Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Oct 2024 Primary endpoint has not been met (Change from Baseline in the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test [ Time Frame: Baseline to Day 84 ]) , according to a SAGE Therapeutics media release
08 Oct 2024 Results published in a SAGE Therapeutics media release
08 Oct 2024 According to a SAGE Therapeutics media release, company today announced topline results from LIGHTWAVE, in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD). Based on these data, the Company does not plan further clinical development of dalzanemdor in AD.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com